Enterovirus A71 Vaccines
Abstract
:1. Introduction
2. Whole EV-A71 Vaccines
2.1. Inactivated Whole EV-A71 Vaccines
2.2. Live-Attenuated Vaccines
3. VLP (Virus Like Particle)-Based Vaccines
4. Recombinant VP1 and P1 Vaccines
5. Synthetic Peptide Vaccines
6. Conclusions and Prospective
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Alexander, J.P., Jr.; Baden, L.; Pallansch, M.A.; Anderson, L.J. Enterovirus 71 infections and neurologic disease--United States, 1977–1991. J. Infect. Dis. 1994, 169, 905–908. [Google Scholar] [CrossRef] [PubMed]
- Ooi, M.H.; Wong, S.C.; Lewthwaite, P.; Cardosa, M.J.; Solomon, T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010, 9, 1097–1105. [Google Scholar] [CrossRef]
- Lee, K.Y. Enterovirus 71 infection and neurological complications. Korean J. Pediat. 2016, 59, 395–401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, L.Y.; Lin, H.Y.; Gau, S.S.; Lu, C.Y.; Hsia, S.H.; Huang, Y.C.; Huang, L.M.; Lin, T.Y. Enterovirus A71 neurologic complications and long-term sequelae. J. Biomed. Sci. 2019, 26, 57. [Google Scholar] [CrossRef] [Green Version]
- Puenpa, J.; Wanlapakorn, N.; Vongpunsawad, S.; Poovorawan, Y. The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in the Asia-Pacific Region. J. Biomed. Sci. 2019, 26, 75. [Google Scholar] [CrossRef] [PubMed]
- Nikonov, O.S.; Chernykh, E.S.; Garber, M.B.; Nikonova, E.Y. Enteroviruses: Classification, Diseases They Cause, and Approaches to Development of Antiviral Drugs. Biochemistry. 2017, 82, 1615–1631. [Google Scholar] [CrossRef]
- Kung, Y.A.; Hung, C.T.; Liu, Y.C.; Shih, S.R. Update on the development of enterovirus 71 vaccines. Expert Opin. Biol. Ther. 2014, 14, 1455–1464. [Google Scholar] [CrossRef]
- Chang, Y.K.; Chen, K.H.; Chen, K.T. Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: A review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development. Rev. Inst. Med. Trop. Sao Paulo 2018, 60, e70. [Google Scholar] [CrossRef] [Green Version]
- Chen, B.S.; Lee, H.C.; Lee, K.M.; Gong, Y.N.; Shih, S.R. Enterovirus and Encephalitis. Front. Microbiol. 2020, 11, 261. [Google Scholar] [CrossRef] [PubMed]
- Lin, J.Y.; Kung, Y.A.; Shih, S.R. Antivirals and vaccines for Enterovirus A71. J. Biomed. Sci. 2019, 26, 65. [Google Scholar] [CrossRef] [Green Version]
- Shih, S.R.; Stollar, V.; Li, M.L. Host factors in enterovirus 71 replication. J. Virol. 2011, 85, 9658–9666. [Google Scholar] [CrossRef] [Green Version]
- Wang, X.; An, Z.; Huo, D.; Jia, L.; Li, J.; Yang, Y.; Liang, Z.; Wang, Q.; Wang, H. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China. Hum. Vaccin. Immunother. 2019, 15, 1183–1190. [Google Scholar] [CrossRef] [Green Version]
- Minor, P.D. Polio eradication, cessation of vaccination and re-emergence of disease. Nat. Rev. Microbiol. 2004, 2, 473–482. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Y.; Li, J.X.; Jin, P.F.; Wang, Y.X.; Zhu, F.C. Enterovirus 71: A whole virion inactivated enterovirus 71 vaccine. Expert Rev. Vaccin. 2016, 15, 803–813. [Google Scholar] [CrossRef] [PubMed]
- Mao, Q.Y.; Wang, Y.; Bian, L.; Xu, M.; Liang, Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev. Vaccin. 2016, 15, 599–606. [Google Scholar] [CrossRef] [PubMed]
- Bek, E.J.; Hussain, K.M.; Phuektes, P.; Kok, C.C.; Gao, Q.; Cai, F.; Gao, Z.; McMinn, P.C. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011, 29, 4829–4838. [Google Scholar] [CrossRef] [PubMed]
- Dong, C.; Liu, L.; Zhao, H.; Wang, J.; Liao, Y.; Zhang, X.; Na, R.; Liang, Y.; Wang, L.; Li, Q. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 2011, 29, 6269–6275. [Google Scholar] [CrossRef]
- Chong, P.; Liu, C.C.; Chow, Y.H.; Chou, A.H.; Klein, M. Review of enterovirus 71 vaccines. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2015, 60, 797–803. [Google Scholar] [CrossRef] [Green Version]
- Zhu, F.; Xu, W.; Xia, J.; Liang, Z.; Liu, Y.; Zhang, X.; Tan, X.; Wang, L.; Mao, Q.; Wu, J.; et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 2014, 370, 818–828. [Google Scholar] [CrossRef] [PubMed]
- Liang, Z.; Mao, Q.; Gao, Q.; Li, X.; Dong, C.; Yu, X.; Yao, X.; Li, F.; Yin, W.; Li, Q.; et al. Establishing China’s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011, 29, 9668–9674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, R.; Liu, L.; Mo, Z.; Wang, X.; Xia, J.; Liang, Z.; Zhang, Y.; Li, Y.; Mao, Q.; Wang, J.; et al. An inactivated enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 2014, 370, 829–837. [Google Scholar] [CrossRef]
- Zhu, F.C.; Meng, F.Y.; Li, J.X.; Li, X.L.; Mao, Q.Y.; Tao, H.; Zhang, Y.T.; Yao, X.; Chu, K.; Chen, Q.H.; et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013, 381, 2024–2032. [Google Scholar] [CrossRef]
- Wei, M.; Meng, F.; Wang, S.; Li, J.; Zhang, Y.; Mao, Q.; Hu, Y.; Liu, P.; Shi, N.; Tao, H.; et al. 2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study. J. Infect. Dis. 2017, 215, 56–63. [Google Scholar] [CrossRef]
- Hu, Y.; Zeng, G.; Chu, K.; Zhang, J.; Han, W.; Zhang, Y.; Li, J.; Zhu, F. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation. Hum. Vaccin. Immunother. 2018, 14, 1517–1523. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lei, D.; Griffiths, E.; Martin, J. WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines. Vaccine 2020, 38, 4917–4923. [Google Scholar] [CrossRef]
- Chang, J.Y.; Chang, C.P.; Tsai, H.H.; Lee, C.D.; Lian, W.C.; Ih Jen, S.; Sai, I.H.; Liu, C.C.; Chou, A.H.; Lu, Y.J.; et al. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. Vaccine 2012, 30, 703–711. [Google Scholar] [CrossRef]
- Chong, P.; Hsieh, S.Y.; Liu, C.C.; Chou, A.H.; Chang, J.Y.; Wu, S.C.; Liu, S.J.; Chow, Y.H.; Su, I.J.; Klein, M. Production of EV71 vaccine candidates. Hum. Vaccin. Immunother. 2012, 8, 1775–1783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cheng, A.; Fung, C.P.; Liu, C.C.; Lin, Y.T.; Tsai, H.Y.; Chang, S.C.; Chou, A.H.; Chang, J.Y.; Jiang, R.H.; Hsieh, Y.C.; et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013, 31, 2471–2476. [Google Scholar] [CrossRef] [PubMed]
- Chou, A.H.; Liu, C.C.; Chang, C.P.; Guo, M.S.; Hsieh, S.Y.; Yang, W.H.; Chao, H.J.; Wu, C.L.; Huang, J.L.; Lee, M.S.; et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS ONE 2012, 7, e34834. [Google Scholar] [CrossRef]
- Chou, A.H.; Liu, C.C.; Chang, J.Y.; Jiang, R.; Hsieh, Y.C.; Tsao, A.; Wu, C.L.; Huang, J.L.; Fung, C.P.; Hsieh, S.M.; et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS ONE 2013, 8, e79783. [Google Scholar] [CrossRef] [PubMed]
- Huang, L.M.; Chiu, C.H.; Chiu, N.C.; Lin, C.Y.; Li, M.T.; Kuo, T.Y.; Weng, Y.J.; Hsieh, E.F.; Tai, I.C. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan. Vaccine 2019, 37, 1827–1835. [Google Scholar] [CrossRef]
- In, H.J.; Lim, H.; Lee, J.A.; Kim, H.J.; Kim, J.W.; Hyeon, J.Y.; Yeo, S.G.; Lee, J.W.; Yoo, J.S.; Choi, Y.K.; et al. An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice. PLoS ONE 2017, 12, e0178259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, S.W.; Cheng, D.; Wang, J.R. Enterovirus A71: Virulence, antigenicity, and genetic evolution over the years. J. Biomed. Sci. 2019, 26, 81. [Google Scholar] [CrossRef]
- Fujii, K.; Sudaka, Y.; Takashino, A.; Kobayashi, K.; Kataoka, C.; Suzuki, T.; Iwata-Yoshikawa, N.; Kotani, O.; Ami, Y.; Shimizu, H.; et al. VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection. J. Virol. 2018, 92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nishimura, Y.; Lee, H.; Hafenstein, S.; Kataoka, C.; Wakita, T.; Bergelson, J.M.; Shimizu, H. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog. 2013, 9, e1003511. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yeh, M.T.; Wang, S.W.; Yu, C.K.; Lin, K.H.; Lei, H.Y.; Su, I.J.; Wang, J.R. A single nucleotide in stem loop II of 5’-untranslated region contributes to virulence of enterovirus 71 in mice. PLoS ONE 2011, 6, e27082. [Google Scholar] [CrossRef]
- Chang, C.K.; Wu, S.R.; Chen, Y.C.; Lee, K.J.; Chung, N.H.; Lu, Y.J.; Yu, S.L.; Liu, C.C.; Chow, Y.H. Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence. Sci. Rep. 2018, 8, 6688. [Google Scholar] [CrossRef] [Green Version]
- Arita, M.; Nagata, N.; Iwata, N.; Ami, Y.; Suzaki, Y.; Mizuta, K.; Iwasaki, T.; Sata, T.; Wakita, T.; Shimizu, H. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J. Virol. 2007, 81, 9386–9395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sadeghipour, S.; Bek, E.J.; McMinn, P.C. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J. Virol. 2013, 87, 1759–1769. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Meng, T.; Kwang, J. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J. Virol. 2014, 88, 5803–5815. [Google Scholar] [CrossRef] [Green Version]
- Tsai, Y.H.; Huang, S.W.; Hsieh, W.S.; Cheng, C.K.; Chang, C.F.; Wang, Y.F.; Wang, J.R. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate. J. Virol. 2019, 93, e02308-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yee, P.T.I.; Tan, S.H.; Ong, K.C.; Tan, K.O.; Wong, K.T.; Hassan, S.S.; Poh, C.L. Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice. Sci. Rep. 2019, 9, 4805. [Google Scholar] [CrossRef]
- Zhao, D.; Sun, B.; Sun, S.; Fu, B.; Liu, C.; Liu, D.; Chu, Y.; Ma, Y.; Bai, L.; Wu, Y.; et al. Characterization of human enterovirus71 virus-like particles used for vaccine antigens. PLoS ONE 2017, 12, e0181182. [Google Scholar] [CrossRef]
- Qian, C.; Liu, X.; Xu, Q.; Wang, Z.; Chen, J.; Li, T.; Zheng, Q.; Yu, H.; Gu, Y.; Li, S.; et al. Recent Progress on the Versatility of Virus-Like Particles. Vaccines (Basel) 2020, 8, 139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chung, Y.C.; Huang, J.H.; Lai, C.W.; Sheng, H.C.; Shih, S.R.; Ho, M.S.; Hu, Y.C. Expression, purification and characterization of enterovirus-71 virus-like particles. World J. Gastroenterol. 2006, 12, 921–927. [Google Scholar] [CrossRef]
- Hu, Y.C.; Hsu, J.T.; Huang, J.H.; Ho, M.S.; Ho, Y.C. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol. Lett. 2003, 25, 919–925. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.L.; Yu, C.I.; Hu, Y.C.; Tsai, T.J.; Kuo, Y.C.; Chi, W.K.; Lin, A.N.; Chiang, B.L. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 2012, 30, 1305–1312. [Google Scholar] [CrossRef]
- Rudd, P.M.; Elliott, T.; Cresswell, P.; Wilson, I.A.; Dwek, R.A. Glycosylation and the immune system. Science 2001, 291, 2370–2376. [Google Scholar] [CrossRef]
- Hyakumura, M.; Walsh, R.; Thaysen-Andersen, M.; Kingston, N.J.; La, M.; Lu, L.; Lovrecz, G.; Packer, N.H.; Locarnini, S.; Netter, H.J. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity. J. Virol. 2015, 89, 11312–11322. [Google Scholar] [CrossRef] [Green Version]
- Zhang, C.; Ku, Z.; Liu, Q.; Wang, X.; Chen, T.; Ye, X.; Li, D.; Jin, X.; Huang, Z. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine 2015, 33, 2335–2341. [Google Scholar] [CrossRef]
- Li, H.Y.; Han, J.F.; Qin, C.F.; Chen, R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 2013, 31, 3281–3287. [Google Scholar] [CrossRef] [PubMed]
- Tsou, Y.L.; Lin, Y.W.; Shao, H.Y.; Yu, S.L.; Wu, S.R.; Lin, H.Y.; Liu, C.C.; Huang, C.; Chong, P.; Chow, Y.H. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease. PLoS Negl. Trop. Dis. 2015, 9, e0003692. [Google Scholar] [CrossRef]
- Yan, Q.; Wu, L.; Chen, L.; Qin, Y.; Pan, Z.; Chen, M. Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges. Vaccine 2016, 34, 4196–4204. [Google Scholar] [CrossRef] [PubMed]
- Ventarola, D.; Bordone, L.; Silverberg, N. Update on hand-foot-and-mouth disease. Clin. Dermatol. 2015, 33, 340–346. [Google Scholar] [CrossRef] [PubMed]
- Zhang, W.; Dai, W.; Zhang, C.; Zhou, Y.; Xiong, P.; Wang, S.; Ye, X.; Liu, Q.; Zhou, D.; Huang, Z. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg. Microbes Infect. 2018, 7, 94. [Google Scholar] [CrossRef] [Green Version]
- Wu, C.N.; Lin, Y.C.; Fann, C.; Liao, N.S.; Shih, S.R.; Ho, M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20, 895–904. [Google Scholar] [CrossRef]
- Zhou, S.L.; Ying, X.L.; Han, X.; Sun, X.X.; Jin, Q.; Yang, F. Characterization of the enterovirus 71 VP1 protein as a vaccine candidate. J. Med. Virol. 2015, 87, 256–262. [Google Scholar] [CrossRef] [PubMed]
- Meng, T.; Kolpe, A.B.; Kiener, T.K.; Chow, V.T.; Kwang, J. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS ONE 2011, 6, e21757. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, X.; Dong, K.; Long, M.; Lin, F.; Gao, Z.; Wang, L.; Zhang, Z.; Chen, X.; Dai, Y.; Wang, H.; et al. Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71. Arch. Virol 2018, 163, 1851–1861. [Google Scholar] [CrossRef] [PubMed]
- Han, X.; Ying, X.L.; Zhou, S.L.; Han, T.; Huang, H.; Jin, Q.; Yang, F.; Sun, Q.Y.; Sun, X.X. Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine. Hum. Vaccin. Immunother 2014, 10, 2220–2226. [Google Scholar] [CrossRef] [Green Version]
- Fournillier, A.; Wychowski, C.; Boucreux, D.; Baumert, T.F.; Meunier, J.C.; Jacobs, D.; Muguet, S.; Depla, E.; Inchauspe, G. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J. Virol. 2001, 75, 12088–12097. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chakrabarti, B.K.; Kong, W.P.; Wu, B.Y.; Yang, Z.Y.; Friborg, J.; Ling, X.; King, S.R.; Montefiori, D.C.; Nabel, G.J. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 2002, 76, 5357–5368. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Foo, D.G.; Alonso, S.; Phoon, M.C.; Ramachandran, N.P.; Chow, V.T.; Poh, C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007, 125, 61–68. [Google Scholar] [CrossRef]
- Foo, D.G.; Alonso, S.; Chow, V.T.; Poh, C.L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes. Infect. 2007, 9, 1299–1306. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.N.; Wang, W.; Duo, J.Y.; Hao, Y.; Ma, C.M.; Li, W.B.; Lin, S.Z.; Gao, X.Z.; Liu, X.L.; Xu, Y.F.; et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010, 28, 7444–7451. [Google Scholar] [CrossRef]
- Aw-Yong, K.L.; Sam, I.C.; Koh, M.T.; Chan, Y.F. Immunodominant IgM and IgG Epitopes Recognized by Antibodies Induced in Enterovirus A71-Associated Hand, Foot and Mouth Disease Patients. PLoS ONE 2016, 11, e0165659. [Google Scholar] [CrossRef] [Green Version]
- Xu, L.; He, D.; Li, Z.; Zheng, J.; Yang, L.; Yu, M.; Yu, H.; Chen, Y.; Que, Y.; Shih, J.W.; et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics 2014, 4, 498–513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huo, C.; Yang, J.; Lei, L.; Qiao, L.; Xin, J.; Pan, Z. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice. Vaccine 2017, 35, 7322–7330. [Google Scholar] [CrossRef]
- Jiang, L.; Fan, R.; Sun, S.; Fan, P.; Su, W.; Zhou, Y.; Gao, F.; Xu, F.; Kong, W.; Jiang, C. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. Vaccine 2015, 33, 6596–6603. [Google Scholar] [CrossRef]
- Mustafa, S.; Abd-Aziz, N.; Saw, W.T.; Liew, S.Y.; Yusoff, K.; Shafee, N. Recombinant Enterovirus 71 Viral Protein 1 Fused to a Truncated Newcastle Disease Virus NP (NPt) Carrier Protein. Vaccines (Basel) 2020, 8, 742. [Google Scholar] [CrossRef] [PubMed]
- Han, J.F.; Cao, R.Y.; Deng, Y.Q.; Tian, X.; Jiang, T.; Qin, E.D.; Qin, C.F. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol. J. 2011, 8, 106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, X.; Peng, W.; Ren, J.; Hu, Z.; Xu, J.; Lou, Z.; Li, X.; Yin, W.; Shen, X.; Porta, C.; et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 2012, 19, 424–429. [Google Scholar] [CrossRef] [Green Version]
- Pardi, N.; Hogan, M.J.; Porter, F.W.; Weissman, D. mRNA vaccines—A new era in vaccinology. Nat. Rev. Drug Discov. 2018, 17, 261–279. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anderson, E.J.; Rouphael, N.G.; Widge, A.T.; Jackson, L.A.; Roberts, P.C.; Makhene, M.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; Pruijssers, A.J.; et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N. Engl. J. Med. 2020, 383, 2427–2438. [Google Scholar] [CrossRef]
- Widge, A.T.; Rouphael, N.G.; Jackson, L.A.; Anderson, E.J.; Roberts, P.C.; Makhene, M.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; Pruijssers, A.J.; et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N. Engl. J. Med. 2020. [Google Scholar] [CrossRef]
Org. | Cells | Dosage | Phase III | Age | Efficacy | Approval Date |
---|---|---|---|---|---|---|
CAMS | KMB-17 | 100 U | March 2012–Februaury 2013 | 6–71 mo | 97.4% | December 2015 |
Vigoo | Vero | 320 U | January 2012–March 2013 | 6–35 mo | 90% | December 2016 |
Sinovac | Vero | 400 U | January 2012–March 2013 | 6–35 mo | 94.8% | December 2015 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Li, M.-L.; Shih, S.-R.; Tolbert, B.S.; Brewer, G. Enterovirus A71 Vaccines. Vaccines 2021, 9, 199. https://doi.org/10.3390/vaccines9030199
Li M-L, Shih S-R, Tolbert BS, Brewer G. Enterovirus A71 Vaccines. Vaccines. 2021; 9(3):199. https://doi.org/10.3390/vaccines9030199
Chicago/Turabian StyleLi, Mei-Ling, Shin-Ru Shih, Blanton S. Tolbert, and Gary Brewer. 2021. "Enterovirus A71 Vaccines" Vaccines 9, no. 3: 199. https://doi.org/10.3390/vaccines9030199
APA StyleLi, M. -L., Shih, S. -R., Tolbert, B. S., & Brewer, G. (2021). Enterovirus A71 Vaccines. Vaccines, 9(3), 199. https://doi.org/10.3390/vaccines9030199